A Phase 4 interventional study of Intravenous ketamine and Cognitive training in Suicide, Attempted, sponsored by Rebecca Price. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-22.
Sponsored by Rebecca Price · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Suicide, Attempted with a site in United States — 53 open to participants now, 58 under way, 1 of them phase 3. Suicide, Attempted · United States.
Among the 149 studies in Suicide, Attempted with a site in United States, this one is the 129th largest by enrollment of the 140 interventional ones that give a count, is one of 8 that started in 2019, is one of 3 in phase 4, and was the 57th registered.
281 studies on the registry are indexed under Suicide, Attempted; 90 are open to participants now.
Browse Suicide, Attempted studies →53 of the 149 studies in Suicide, Attempted with a site in United States are open now. Recruiting first, the newest first:
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 12+
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 13–17
University of Michigan · Sites in United States
Ages 18–65
Ohio State University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 67 Suicide, Attempted studies recruiting now, 34 (51%) set no upper age limit and 32 (48%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8 · Phase 3 6 · Phase 4 3
First in 1999; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 129 across 224 interventional studies indexed under Suicide, Attempted.
Median enrollment 117 across the 140 interventional studies, 225 across the 7 observational. Of the 87 that completed or were terminated, 30 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 149 have an industry lead sponsor. The 10 most frequent:
Rebecca Price is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Rebecca Price has 2 studies filed under Suicide, Attempted — fewer than ten, so there is no comparison to draw.
30 of the studies in Suicide, Attempted with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04763343Phase 3Tatiana Falcone, MDKetamine Treatment of Youth Suicide Attempters | 2027-02-28 |
| NCT07170657University of Texas Southwestern Medical CenterTeen Recovery Through Inspiration, Support, and Empowerment | 2026-11 |
| NCT06460220Jennifer HughesSAFETY-Parent: Online Learning Module to Support Parents of Suicidal Youth | 2026-12 |
| NCT06285708Ohio State UniversityEnhancing the Effectiveness of Prolonged Exposure Among Suicidal Individuals With PTSD | 2026-12 |
| NCT04578938Rebecca PriceKetamine + Cognitive Training for Suicidality in the Medical Setting | 2026-12-02 |
Add all 30 to your calendar (.ics) → With an account.
Among the 149 studies in Suicide, Attempted with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project seeks to identify the acute and longer-term impact of a single dose of intravenous ketamine among suicidal patients referred for psychiatric consultation/liaison in the medical inpatient setting. The investigators will then test whether ketamine's rapid effects can be extended by introducing helpful information delivered by a computer-based training protocol. This work could ultimately lead to the ability to treat suicidality more efficiently and with broader dissemination by rapidly priming the brain for helpful forms of learning.
NOTE: In the course of this pilot study, both the primary and secondary outcome measures were supplemented to provide additional, complementary information on the clinical effects of the study interventions, based on confirmation (through study team experience) of the feasibility of acquiring such additional information in the context of our study population, setting, and design.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants will:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Intravenous ketamine · Behavioral: Cognitive training
Drug: Intravenous ketamine · Behavioral: Sham Training
Single subanesthetic infusion of ketamine (0.5mg/kg)
8 sessions of computer-based cognitive training
8 sessions of computer-based sham training
Montgomery Asberg Depression Rating Scale
depression severity; range 0-60; high score=worse outcome
Time frame: infusion +24 hours
Montgomery Asberg Depression Rating Scale
depression severity; range 0-60; high score=worse outcome
Time frame: infusion +5 days
Montgomery Asberg Depression Rating Scale
depression severity; range 0-60; high score=worse outcome
Time frame: infusion +12 days
Montgomery Asberg Depression Rating Scale
depression severity; range 0-60; high score=worse outcome
Time frame: infusion +1 month
Montgomery Asberg Depression Rating Scale
depression severity; range 0-60; high score=worse outcome
Time frame: infusion +3 months
Montgomery Asberg Depression Rating Scale
depression severity; range 0-60; high score=worse outcome
Time frame: infusion +6 months
Adult Suicide Ideation Questionnaire (Past Day Version)
suicidal ideation/thoughts; range 0-150; high score=worse outcome
Time frame: infusion +24 hours
Adult Suicide Ideation Questionnaire (Past Day Version)
suicidal ideation/thoughts; range 0-150; high score=worse outcome
Time frame: infusion +5 days
Adult Suicide Ideation Questionnaire (Past Day Version)
suicidal ideation/thoughts; range 0-150; high score=worse outcome
Time frame: infusion +12 days
Adult Suicide Ideation Questionnaire
suicidal ideation/thoughts; range 0-150; high score=worse outcome
Time frame: infusion +1 month
Adult Suicide Ideation Questionnaire
suicidal ideation/thoughts; range 0-150; high score=worse outcome
Time frame: infusion +3 months
Adult Suicide Ideation Questionnaire
suicidal ideation/thoughts; range 0-150; high score=worse outcome
Time frame: infusion +6 months
Number of Participants With Occurrence of Suicidal Behaviors Per Medical Chart Review
Number of participants with occurrence of any suicidal act (derived from medical chart) including: re-attempt, re-hospitalization for suicidality, or completed suicide
Time frame: infusion +6 months
Number of Participants Reporting Suicidal Behaviors Per the Columbia Suicide Severity Rating Scale (CSSRS)
Number of participants with occurrence of any suicidal act (derived from Columbia Suicide Severity Rating Scale interview; each of the following items was scored yes/no for the period since last assessment: re-attempt, re-hospitalization for suicidality, or completed suicide. Analyzed outcome measure is # of participants with 1 or more 'yes' responses.
Time frame: infusion +6 months
Quick Inventory of Depressive Symptoms
Self-reported depression (range: 0-27; higher scores = worse outcome)
Time frame: infusion +24 hours
Quick Inventory of Depressive Symptoms
Self-reported depression (range: 0-27; higher scores = worse outcome)
Time frame: infusion +5 days
Quick Inventory of Depressive Symptoms
Self-reported depression (range: 0-27; higher scores = worse outcome)
Time frame: infusion +12 days
Quick Inventory of Depressive Symptoms
Self-reported depression (range: 0-27; higher scores = worse outcome)
Time frame: infusion +1 month
Quick Inventory of Depressive Symptoms
Self-reported depression (range: 0-27; higher scores = worse outcome)
Time frame: infusion +3 months
Quick Inventory of Depressive Symptoms
Self-reported depression (range: 0-27; higher scores = worse outcome)
Time frame: infusion +6 months
Scale for Suicide Ideation
suicidal ideation/thoughts; range 0-38; high score=worse outcome
Time frame: infusion +24 hours
Scale for Suicide Ideation
suicidal ideation/thoughts; range 0-38; high score=worse outcome
Time frame: infusion +5 days
Scale for Suicide Ideation
suicidal ideation/thoughts; range 0-38; high score=worse outcome
Time frame: infusion +12 days
Scale for Suicide Ideation
suicidal ideation/thoughts; range 0-38; high score=worse outcome
Time frame: infusion +1 month
Scale for Suicide Ideation
suicidal ideation/thoughts; range 0-38; high score=worse outcome
Time frame: infusion +3 months
Scale for Suicide Ideation
suicidal ideation/thoughts; range 0-38; high score=worse outcome
Time frame: infusion +6 months
| Milestone | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Started | 7 | 9 |
| Completed | 7 | 9 |
| Not completed | 0 | 0 |
depression severity; range 0-60; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Montgomery Asberg Depression Rating Scale | 18.43 ± 8.5 | 15.44 ± 10.9 |
depression severity; range 0-60; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Montgomery Asberg Depression Rating Scale | 19.14 ± 9.8 | 16.13 ± 9.2 |
depression severity; range 0-60; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Montgomery Asberg Depression Rating Scale | 13.67 ± 14.2 | 17.29 ± 11.9 |
depression severity; range 0-60; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Montgomery Asberg Depression Rating Scale | 20.67 ± 7.6 | 14.00 ± 13.4 |
depression severity; range 0-60; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Montgomery Asberg Depression Rating Scale | 13.00 ± 13.6 | 14.71 ± 10.2 |
depression severity; range 0-60; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Montgomery Asberg Depression Rating Scale | 13.20 ± 14.7 | 17.43 ± 9.9 |
suicidal ideation/thoughts; range 0-150; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Adult Suicide Ideation Questionnaire (Past Day Version) | 32.67 ± 8.45 | 41.89 ± 38.6 |
suicidal ideation/thoughts; range 0-150; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Adult Suicide Ideation Questionnaire (Past Day Version) | 20.00 ± 9.98 | 22.88 ± 10.7 |
suicidal ideation/thoughts; range 0-150; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Adult Suicide Ideation Questionnaire (Past Day Version) | 17.17 ± 13.4 | 31.86 ± 34.6 |
suicidal ideation/thoughts; range 0-150; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Adult Suicide Ideation Questionnaire | 23.60 ± 22.9 | 41.83 ± 48.0 |
suicidal ideation/thoughts; range 0-150; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Adult Suicide Ideation Questionnaire | 25.20 ± 26.2 | 37.50 ± 46.5 |
suicidal ideation/thoughts; range 0-150; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Adult Suicide Ideation Questionnaire | 29.5 ± 40.3 | 45.75 ± 60.9 |
Number of participants with occurrence of any suicidal act (derived from medical chart) including: re-attempt, re-hospitalization for suicidality, or completed suicide
| Participants | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Number of Participants With Occurrence of Suicidal Behaviors Per Medical Chart Review | 3 | 4 |
Number of participants with occurrence of any suicidal act (derived from Columbia Suicide Severity Rating Scale interview; each of the following items was scored yes/no for the period since last assessment: re-attempt, re-hospitalization for suicidality, or completed suicide. Analyzed outcome measure is # of participants with 1 or more 'yes' responses.
| Participants | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Number of Participants Reporting Suicidal Behaviors Per the Columbia Suicide Severity Rating Scale (CSSRS) | 1 | 1 |
Self-reported depression (range: 0-27; higher scores = worse outcome)
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Quick Inventory of Depressive Symptoms | 12.83 ± 4.1 | 11.22 ± 6.0 |
Self-reported depression (range: 0-27; higher scores = worse outcome)
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Quick Inventory of Depressive Symptoms | 9.86 ± 5.8 | 9.50 ± 6.9 |
Self-reported depression (range: 0-27; higher scores = worse outcome)
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Quick Inventory of Depressive Symptoms | 8.33 ± 7.1 | 9.86 ± 7.3 |
Self-reported depression (range: 0-27; higher scores = worse outcome)
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Quick Inventory of Depressive Symptoms | 9.60 ± 3.4 | 9.33 ± 7.0 |
Self-reported depression (range: 0-27; higher scores = worse outcome)
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Quick Inventory of Depressive Symptoms | 10.60 ± 7.1 | 9.17 ± 7.5 |
Self-reported depression (range: 0-27; higher scores = worse outcome)
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Quick Inventory of Depressive Symptoms | 10.00 ± 10.0 | 12.25 ± 10.6 |
suicidal ideation/thoughts; range 0-38; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Scale for Suicide Ideation | 8.50 ± 12.0 | 0.80 ± 1.3 |
suicidal ideation/thoughts; range 0-38; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Scale for Suicide Ideation | 0.50 ± .71 | 6.60 ± 9.4 |
suicidal ideation/thoughts; range 0-38; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Scale for Suicide Ideation | — | 4.50 ± 9.0 |
suicidal ideation/thoughts; range 0-38; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Scale for Suicide Ideation | 13.00 | 4.67 ± 7.2 |
suicidal ideation/thoughts; range 0-38; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Scale for Suicide Ideation | 4.00 ± 7.3 | 5.83 ± 9.2 |
suicidal ideation/thoughts; range 0-38; high score=worse outcome
| score on a scale | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| Scale for Suicide Ideation | 5.40 ± 12.1 | 6.86 ± 9.2 |
Collected over 24 hours. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ketamine + Cognitive Training | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Ketamine + Sham Training | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| Event | Ketamine + Cognitive Training | Ketamine + Sham Training |
|---|---|---|
| difficulty sleeping: too littlePsychiatric disorders | 3/7 | 3/9 |
| emotional indifferencePsychiatric disorders | 3/7 | 2/9 |
| nauseaGastrointestinal disorders | 3/7 | 0/9 |
| anxietyPsychiatric disorders | 2/7 | 3/9 |
| headacheNervous system disorders | 2/7 | 3/9 |
| sweatingGeneral disorders | 2/7 | 3/9 |
| constipationGastrointestinal disorders | 2/7 | 2/9 |
| dizzinessNervous system disorders | 2/7 | 2/9 |
| decreased energyGeneral disorders | 1/7 | 2/9 |
| increased appetiteGastrointestinal disorders | 1/7 | 2/9 |
| Age, Continuous(years) | Ketamine + Cognitive Training | Ketamine + Sham Training | Total |
|---|---|---|---|
| Mean | 32.29 ± 14.80 | 35.44 ± 17.74 | 34.06 ± 16.06 |
| Sex/Gender, Customized(Participants) | Ketamine + Cognitive Training | Ketamine + Sham Training | Total |
|---|---|---|---|
| Male | 2 | 5 | 7 |
| Female | 5 | 3 | 8 |
| Transgender (female-to-male) | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Ketamine + Cognitive Training | Ketamine + Sham Training | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 4 |
| Not Hispanic or Latino | 6 | 5 | 11 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Ketamine + Cognitive Training | Ketamine + Sham Training | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 5 | 8 | 13 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Montgomery Asberg Depression Rating Scale(units on a scale) | Ketamine + Cognitive Training | Ketamine + Sham Training | Total |
|---|---|---|---|
| Mean | 39 ± 6.4 | 36.8 ± 6.3 | 37.8 ± 6.2 |
| Adult Suicide Ideation Questionnaire(units on a scale) | Ketamine + Cognitive Training | Ketamine + Sham Training | Total |
|---|---|---|---|
| Mean | 85.0 ± 35.2 | 96.6 ± 31.5 | 91.9 ± 32.3 |
| Quick Inventory of Depressive Symptoms(units on a scale) | Ketamine + Cognitive Training | Ketamine + Sham Training | Total |
|---|---|---|---|
| Mean | 17.8 ± 3.1 | 14.4 ± 5.95 | 15.9 ± 5.1 |
| Scale for Suicide Ideation(units on a scale) | Ketamine + Cognitive Training | Ketamine + Sham Training | Total |
|---|---|---|---|
| Mean | 30.3 ± 2.2 | 29.3 ± 1.7 | 29.6 ± 1.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Mar 2022, 26 months.
Results were first posted in Jan 2023, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rebecca Price